Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …

Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP)
and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for …

abstract Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and
glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along …

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …

The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight …

Gut hormones have many key roles in the control of metabolism, as they target diverse
tissues involved in the control of intestinal function, insulin secretion, nutrient assimilation …

Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose homeostasis, reduce
bodyweight, and over time benefit cardiovascular health in type 2 diabetes mellitus (T2DM) …